statistical procedure used to arrive at their con clusions may be â€˜¿ elegant',its utility is limited by the quality ofdata being analysed.
Two issues deserve further discussion. The first relates to the duration of antidepressant medication before a patient can be considered treatment refractory. The studies reviewed used antidepressants for a minimum ofthree weeks before adding lithium. However, there is evidence (Quitkin et al, 1984; Georgotas et a!, 1986 ) that up to 25% of patients treated with an adequate dose of antidepressant medication will not respond until weeks four to six of treatment. Given that many of the patients used in the meta-analysis were prescribed lithium after only three weeks, one has to question whether clinical improvement was attributable to lithium or was, in fact, a delayed response to the primary antidepressant. Dr Austin et al state that â€oe¿ it is doubtful that many clinicians would in practice wait more than four weeks before changing to another treatment if no response is seenâ€•.However, if the evidence suggests that six weeks is required for an adequate trial of an antidepressant, then it is incumbent on the clinician to persist with that treatment rather than pre maturely adding another medication with its own risks and side-effects. The second issue pertains to the criteria used to define response to lithium augmentation. Three of the five studies used a @40â€"50% reduction in Hamilton Rating Scale for Depression (HRSD; Hamilton, 1960) score and a fourth study used a @2 point decrease on a 15-point nurses rating scale.
Given that the mean HRSD entry scores for those studies ranged from 20â€"34, many patients fulfilling criteria for response could still have had scores con sistent with mild to moderate levels of depression. Therefore, in these studies, response did not necessarily equate with remission of the depressive illness.
Given these considerations, we must await further found to have Schneider's first rank symptoms of schizophrenia (CATEGOS+) on project diagnosis (Littlewood & Lipsedge, 1981) , and indeed the notion of bouffee dÃ©lirantehas been most typically developed in studies in peasant communities. Never theless, their use of the RDC minimum period of illness for schizophrenia (two weeks) would not include any patients satisfying our Jasperian criteria of â€˜¿ reactivity' (ibid). As they point out, our current interpretations involve a complex interplay between the biological and the political: simple â€˜¿ misdiagnosis',with its implications for better education of psychiatrists, is figures showed no overall increase in subsequent schizophrenia for the year in question, compared with the four control years, which hardly accords with our expectations of a causal agent. Many other reviews of schizophrenia, while comprehensive in analysis, do tend to focus narrowly on biological data, ignoring the more difficult problems of social research. In particular, it seems that not enough attention has been paid to the pathoplastic, as opposed to the pathogenic, effects of brain abnormalities.
Yet a key area of Afro-Caribbean studies is the problem of quantifying the true presence of schizo phrenia. As Glover (1989) has pointed out, if symp toms are more florid in this group, â€oe¿ then a higher proportion ofCaribbean schizophrenics would reach the level required for diagnosis by standardized instrumentsâ€•, and fewer would have â€oe¿ subclinical ill nessâ€•. Yet there have been no community surveys of schizophrenia and ethnicity in this country; all the reports rely on the data of admission and/or presen tation to hospital. Such community studies are, of course, notoriously difficult to carry out, but vital in an area of such social controversy and aetiological importance. In addition, we have an extremely un certain census base from 1981, and the increased numbers ofblack males in prisons, and under Mental Health Act Sections, seem to point to a behavioural prominence thatmay wellbedistorting the admission figures. Given the community care policies of today, and the increased pressure on acute psychiatry beds (especially in the inner-city areas with high pro portions of Afro-Caribbean residents), is it not likely that suchindividualswill havemore obvious admission needs? A further vital issue is the notion of cross-cultural validity in terms of the instruments used. Dr Wessely et a! admitted in their study that these were not established, and agreed that other biases in their control group might have been present. As a clinician working among a significant Afro Caribbean population, it is quite clear to me that there is an excess of admissions, both first and sub sequent, for schizophrenia in this group. However, it is also clear that they seem to have much less family support, to be more often technically homeless, and in a number of instances seem to have preferentially ended up in the British health care system. This is despite their families residing in North America, Africa or the Caribbean. Seven out of twelve current African or Caribbean in-patients (on our 20-bed acute ward) fit this concept, and five have a schizo phrenic illness. Several individuals have, literally, been sent to Britain for care, by relatives aware of the limited resources available for psychotic individuals in the Third World, or unable to cope with the expenses liable in America. The patterns of mi gration in the post-war period have also been much more complex than the simple model of West Indians coming to Britain, and I would suggest that there may well have been a secondary selective process.
Overall, the Afro-Caribbean debate seems to be worryingly unresolved. This is due to an under emphasis on the less medical, less â€˜¿ hard', and more difficult to fund areas of research. Yet if we do not balance out such research needs we are at risk of creating a top-heavy viral/genetic theory that has no foundation in social facts. Whatever the quality of such biological research, and it seems to me in general to be first class, this will nevertheless create a distrust of psychiatrists among ethnic groups
